In today’s briefing:
- BeiGene Ltd (6160.HK/BGNE.US/688235.CH) – Valuation Remodeling if the TIGIT Project Fails
BeiGene Ltd (6160.HK/BGNE.US/688235.CH) – Valuation Remodeling if the TIGIT Project Fails
- With Roche’s failure of several clinical trials on TIGIT project tiragolumab, the market’s future expectations on this target have discounted. Investors may need to get prepared in advance.
- Ociperlimab means a lot to BeiGene. If ociperlimab fails, BeiGene would have no big catalyst for a long time. BeiGene’s label of superior global R&D capability + potential BIC doesn’t hold water.
- Without ociperlimab, BeiGene’s valuation could fall back to about RMB60 billion to RMB80 billion. If the valuation is finally in line with Innovent, it would be no surprising.
Before it’s here, it’s on Smartkarma
